Stanley Cohan

5.5k total citations
94 papers, 1.6k citations indexed

About

Stanley Cohan is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, Stanley Cohan has authored 94 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Pathology and Forensic Medicine, 22 papers in Oncology and 15 papers in Neurology. Recurrent topics in Stanley Cohan's work include Multiple Sclerosis Research Studies (51 papers), Polyomavirus and related diseases (19 papers) and Peripheral Neuropathies and Disorders (7 papers). Stanley Cohan is often cited by papers focused on Multiple Sclerosis Research Studies (51 papers), Polyomavirus and related diseases (19 papers) and Peripheral Neuropathies and Disorders (7 papers). Stanley Cohan collaborates with scholars based in United States, Switzerland and Germany. Stanley Cohan's co-authors include Manuel Yepes, Timothy A. Coleman, Maria Sandkvist, Elizabeth Smith, Daniel A. Lawrence, Kyle Smoot, Dieter Schellinger, Elisabeth B. Lucassen, E G Grant and J. David Richardson and has published in prestigious journals such as JAMA, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Stanley Cohan

91 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stanley Cohan United States 21 592 314 281 243 229 94 1.6k
Halina Bartosik-Psujek Poland 21 605 1.0× 271 0.9× 212 0.8× 185 0.8× 159 0.7× 116 1.3k
Albert J. Augustin Germany 35 333 0.6× 825 2.6× 148 0.5× 197 0.8× 258 1.1× 180 5.2k
Simon Faissner Germany 20 534 0.9× 304 1.0× 312 1.1× 180 0.7× 113 0.5× 61 1.3k
Takehira Yamamura Japan 26 390 0.7× 551 1.8× 99 0.4× 603 2.5× 395 1.7× 104 2.7k
Liqun Yang China 26 339 0.6× 715 2.3× 153 0.5× 235 1.0× 253 1.1× 95 2.3k
Asha Kallianpur United States 25 133 0.2× 486 1.5× 129 0.5× 180 0.7× 199 0.9× 59 1.8k
Sun On Chan Hong Kong 29 383 0.6× 955 3.0× 95 0.3× 303 1.2× 103 0.4× 147 2.5k
Tatiana Koudriavtseva Italy 20 646 1.1× 192 0.6× 290 1.0× 172 0.7× 85 0.4× 58 1.3k
Xin Wei China 22 179 0.3× 574 1.8× 58 0.2× 329 1.4× 143 0.6× 92 1.8k
Luigi Bergamaschini Italy 29 324 0.5× 459 1.5× 123 0.4× 116 0.5× 155 0.7× 79 2.6k

Countries citing papers authored by Stanley Cohan

Since Specialization
Citations

This map shows the geographic impact of Stanley Cohan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stanley Cohan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stanley Cohan more than expected).

Fields of papers citing papers by Stanley Cohan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stanley Cohan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stanley Cohan. The network helps show where Stanley Cohan may publish in the future.

Co-authorship network of co-authors of Stanley Cohan

This figure shows the co-authorship network connecting the top 25 collaborators of Stanley Cohan. A scholar is included among the top collaborators of Stanley Cohan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stanley Cohan. Stanley Cohan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fox, Robert J., Stanley Cohan, Yang Mao‐Draayer, et al.. (2025). Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study. Multiple Sclerosis Journal. 31(6). 706–718.
2.
Williams, Mitzi, Lilyana Amezcua, Stanley Cohan, et al.. (2024). Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups. Neurology. 103(3). e209610–e209610. 3 indexed citations
3.
Patel, Anisha M., Irina Yermilov, Sarah N. Gibbs, et al.. (2024). Development and validation of a claims-based algorithm to identify patients with Neuromyelitis Optica Spectrum disorder. Journal of the Neurological Sciences. 463. 123110–123110. 1 indexed citations
4.
Williams, Mitzi, Lilyana Amezcua, Ángel Chinea, et al.. (2023). Real-World Safety and Effectiveness After 5 Years of Dimethyl Fumarate Treatment in Black and Hispanic Patients with Multiple Sclerosis in ESTEEM. Neurology and Therapy. 12(5). 1669–1682. 6 indexed citations
5.
Cohan, Stanley, Ralph H. B. Benedict, Bruce Cree, et al.. (2022). The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis. CNS Drugs. 36(7). 703–719. 28 indexed citations
6.
7.
8.
Cohan, Stanley, Barry Hendin, Anthony T. Reder, et al.. (2021). Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex). CNS Drugs. 35(7). 743–767. 1 indexed citations
9.
Pratap, Abhishek, Daniel Grant, Ashok Vegesna, et al.. (2020). Evaluating the Utility of Smartphone-Based Sensor Assessments in Persons With Multiple Sclerosis in the Real-World Using an App (elevateMS): Observational, Prospective Pilot Digital Health Study. JMIR mhealth and uhealth. 8(10). e22108–e22108. 51 indexed citations
10.
Spinelli, Kateri J., et al.. (2020). Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry. BMC Neurology. 20(1). 439–439. 5 indexed citations
11.
Williams, Mitzi, Lilyana Amezcua, Darin T. Okuda, et al.. (2020). Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 3-Year Results from ESTEEM. Neurology and Therapy. 9(2). 483–493. 21 indexed citations
12.
Cohan, Stanley, Harold Moses, Jonathan Calkwood, et al.. (2018). Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY). Multiple Sclerosis and Related Disorders. 22. 27–34. 42 indexed citations
13.
Chen, Shih‐Yin, Farrah Pompilus, Sophie Cleanthous, et al.. (2017). Development of a Gait Module to Complement the 12-item Patient-Reported Multiple Sclerosis Walking Scale (P1.374). Neurology. 88(16_supplement). 1 indexed citations
14.
15.
16.
Butzkueven, Helmut, Stanley Cohan, Tjalf Ziemssen, et al.. (2015). Baseline characteristics and interim analysis results of TRANSITION: a 2-year observational study evaluating the safety profile of patients with multiple sclerosis who switched from natalizumab to fingolimod. Multiple Sclerosis Journal. 21. 2 indexed citations
17.
18.
Capkun, Gorana, Frank Dahlke, Raquel Lahoz, et al.. (2015). Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US Department of Defense administrative claims database. Multiple Sclerosis and Related Disorders. 4(6). 546–554. 90 indexed citations
19.
Wigder, Herbert N., et al.. (1996). ACEP Chest Pain Policy: Emergency Physician Awareness. Annals of Emergency Medicine. 27(5). 606–609. 13 indexed citations
20.
Cohan, Stanley. (1990). Pharmacology of Calcium Antagonists: Clinical Relevance in Neurology. European Neurology. 30(2). 28–30. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Halina Bartosik-Psujek Breakdown of academic impact, for papers by Albert J. Augustin Breakdown of academic impact, for papers by Simon Faissner Breakdown of academic impact, for papers by Takehira Yamamura Breakdown of academic impact, for papers by Liqun Yang Breakdown of academic impact, for papers by Asha Kallianpur Breakdown of academic impact, for papers by Sun On Chan Breakdown of academic impact, for papers by Tatiana Koudriavtseva Breakdown of academic impact, for papers by Xin Wei Breakdown of academic impact, for papers by Luigi Bergamaschini
Rankless by CCL
2026